PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Am Chem Soc. Author manuscript; available in PMC Apr 19, 2010.
Published in final edited form as:
PMCID: PMC2856597
NIHMSID: NIHMS61237
Early Intermediate in Human Prion Protein Folding as Evidenced by Ultrarapid Mixing Experiments
Adrian C. Apetri,£ Kosuke Maki,§ Heinrich Roder,* and Witold K. Surewicz*
Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio 44106
Basic Science Division, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111
To whom correspondence should be addressed. Witold Surewicz, wks3/at/case.edu; Heinrich Roder, roder/at/fccc.edu
£Current address: Howard Hughes Medical Institute, Yale University, New Haven, CT
§Current address: Department of Physics, University of Tokyo, Tokyo 113-0033, Japan
An important step towards understanding the mechanism of the PrPC to PrPSc conversion is to elucidate the folding pathway(s) of the prion protein. Based on stopped-flow measurements, we recently proposed that the prion protein folds via a transient intermediate formed on the sub-millisecond time-scale, and mutations linked to familial diseases result in a pronounced increase in the population of this intermediate. Here, we have extended these studies to continuous flow measurements using a capillary mixing system with a time resolution of ~ 100 μs. This allowed us to directly observe two distinct phases in folding of the recombinant human prion protein 90–231, providing unambiguous evidence for rapid accumulation of an early intermediate (with a time constant of ~50 μs), followed by a rate-limiting folding step (with a time constant of ~700 μs). The present study also clearly demonstrates that the population of the intermediate is significantly increased at mildly acidic pH and in the presence of urea. A similar three-state folding behavior was observed for Gerstmann-Straussler-Scheinker disease- associated F198S mutant, in which case the population of an intermediate was greatly increased as compared to the wild-type protein. Overall, the present data strongly suggest that this partially structured intermediate may be a direct monomeric precursor of the misfolded PrPSc oligomer.
Prion diseases, or transmissible spongiform encephalopathies (TSEs), are fatal neurodegenerative disorders that include scrapie in sheep, bovine spongiform encephalopathy in cattle, chronic wasting disease in cervids, and Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker disease and fatal familial insomnia in humans 17. All of these diseases, including those that arise spontaneously, by genetic mutation or by infection, are associated with the conformational conversion of a normal (cellular) prion protein, PrPC, into a misfolded isoform, PrPSc. According to the “protein-only” hypothesis, PrPSc itself is the infectious TSE pathogen; it is believed to self-perpetuate by a mechanism involving binding to PrPC and the recruitment of the latter protein to the PrPSc state 1, 2. Though not universally accepted, this model is supported by a wealth of experimental observations 19, including the recent success in generating infectious PrPSc in vitro10, 11. Furthermore, the general concept that proteins alone can act as infectious agents has been proven in recent studies on conformation-based prion inheritance in yeast and fungi 1214.
PrPC is a 231-residue glycoprotein composed of a highly flexible N-terminal part and a globular C-terminal domain comprising three α-helices and two very short β-strands 1518. Although they appear to have identical covalent structures 19, PrPC and PrPSc differ profoundly in their biophysical properties. PrPC is monomeric, proteinase-sensitive and soluble in non-ionic detergents, whereas PrPSc is oligomeric, partially resistant to proteinase digestion and highly insoluble 17. Furthermore, in contrast to the largely α-helical PrPC, the pathogenic PrPSc appears to have a high content of β-sheet structure 20, 21, although no high-resolution structural data is yet available for the latter conformer.
Despite numerous studies, little is known about the mechanism of the PrPC→PrPSc conversion. An important step towards understanding this mechanism is to elucidate the folding pathway(s) of the prion protein in an effort to identify the direct monomeric precursor of the oligomeric PrPSc species. While initial experiments suggested that the prion protein folds very rapidly by a two-state mechanism 22, our recent kinetic stopped-flow studies using single-Trp variants of huPrP90–231 revealed that during refolding from urea the human prion protein populates a partially structured intermediate 23, 24. This early intermediate, which accumulates within the dead-time of stopped-flow experiments (~1 ms), was detected by an incomplete recovery of the fluorescence amplitude upon extrapolation of experimental data to time zero (the presence of so-called burst phase), as well as a well-defined slope change in a plot of the logarithm of the rate constant for folding versus urea concentration (chevron plot). While the above criteria have been widely used to detect and characterize intermediates in protein folding 2527, some authors argue that there might be alternative explanations for the presence of burst phases and nonlinearities in chevron plots 28, 29. Therefore, in an attempt to obtain a more direct evidence for the population of the intermediate ensemble in prion protein folding, we have extended our kinetic studies to measurements using a continuous-flow capillary mixing instrument 30. This instrumentation makes it possible to measure the kinetics of folding on a substantially shorter time scale as compared to conventional stopped-flow methods 31. The present data provides unambiguous evidence for an early intermediate which accumulates on the time scale of hundreds of μsec, followed by a rate-limiting folding step on the millisecond time scale. Furthermore, continuous-flow experiments demonstrate a greatly increased population of the intermediate for the disease-related prion protein mutant, reinforcing our hypothesis that the intermediate state may represent a crucial monomeric precursor of PrPSc aggregates.
Protein Expression and Purification
The plasmid encoding huPrP90-231 with an N-terminal linker containing His-6 tail and a thrombin cleavage site was described previously 32, 33. The W99F/Y218W huPrP90-231 variant was constructed by site-directed mutagenesis using appropriate primers and the QuikChange kit (Stratgene). The proteins were expressed, cleaved with thrombin and purified according to the previously described protocol 32, 34. The concentration of purified protein was determined spectrophotometrically using the molar extinction coefficient, ε276, of 21,640 M−1cm−1.
Continuous-flow measurements
The proteins were first fully unfolded in 6 M urea buffered with 20 mM Gly-HCl, pH 3. The kinetics of the refolding reactions were studied by diluting the fully unfolded protein at a 1:10 ratio into refolding buffer (50 mM phosphate, pH 7.0 or 50 mM sodium acetate, pH 4.8) containing urea at a desired concentration. In most experiments, the final protein concentration was 40 μM. The reactions were monitored at 5°C by fluorescence above 324 nm (excitation at 288 nm) using the continuous flow capillary mixing method described by Shastry et al. 30 at total flow rates of 0.825 and 1.375 ml/s. The dead time of the capillary mixer was determined by measuring the quenching of N-acetyl tryptophan amide fluorescence by N-bromosuccinimide at several quencher concentrations. Under our present experimental conditions (5°C; final urea concentration of ~ 0.6 M) the measured dead times at 0.825 and 1.375 ml/s total flow rates were 180 and 120 μs, respectively. Each protein refolding reaction was measured at least 5 times. The kinetic data were analyzed according to a three-state sequential model (Scheme I) using the IGOR Pro software (Wavemetrics Inc). We also made the conventional assumption that there is a linear dependence between the logarithm of an elementary rate constant, kij, and denaturant concentration:
equation M1
(1)
where kij0 and mij represent the microscopic rate constant in the absence of denaturant and the urea dependence of the rate constant, respectively.
The observed rate constants and corresponding amplitudes were obtained directly from the best fit of the kinetic traces at each denaturant concentration. The elementary rate constants and m-values were systematically varied to obtain a satisfactory match between calculated and measured data, as previously described 35.
According to the three-state model (Scheme I), the temporal evolution of native (N), intermediate (I), and unfolded (U) species under a particular set of experimental conditions can be described in terms of a system of three differential equations 36. The solutions are sums of two exponential terms describing the dependence of the populations of N, I, and U on reaction time and denaturant concentration. The time dependent accumulation of N, I, and U was modeled at 0 M, 1 M, 2 M, and 4 M urea using a IGOR Pro routine as previously described 36.
Double Exponential Folding of huPrP90-231
As in our previous stopped-flow experiments 23, 24, the present studies were performed using huPrP90-231 variant with a single Trp residue introduced by a conservative replacement of Tyr at position 218. The protein was first denatured in 6 M urea at pH 3, and refolding was triggered by rapid 1:10 dilution to 50 mM phosphate buffer, pH 7, containing various concentrations of the denaturant (0.7–3.5 M urea). The progress of the reaction was followed at 5°C using the continuous-flow method by monitoring the decay of fluorescence of Trp 218, which is highly quenched in the native state 23. Since the refolding reactions were not completed within the time frame of the continuous-flow experiment (i.e. ~ 500 μs), the flow-through from kinetic measurements was collected and its fluorescence was measured at a later time by passing it through the capillary system. The final fluorescence amplitudes obtained in this manner were used as constraints for fitting the exponential decays corresponding to the refolding of huPrP90-231.
Figure 1 shows a representative kinetic trace for the refolding of huPrP90-231 in the presence of 1.1 M urea, together with best fits to single and double exponential functions and residuals of these fits. While the fit to a single exponential is very poor (Figure 1A), the kinetic trace is well described by a sum of two exponential phases with time constants of 19,000 and 1,400 s−1 (Figure 1B). A similar situation was encountered for refolding curves at other urea concentrations studied; in each case the continuous flow kinetic traces could not be fit to a single exponential function, whereas the double exponential fits were very good (Figure 2). Such a double exponential character of kinetics traces clearly indicates the accumulation of an intermediate during prion protein folding, with the fast phase corresponding to the formation of an intermediate ensemble and the slower phases corresponding to the rate-limiting step of native state formation.
Figure 1
Figure 1
The time-course of tryptophan fluorescence changes during the refolding of huPrP90-231 in 50 mM phosphate buffer, pH 7.0, in the presence of 1.1 M urea
Figure 2
Figure 2
Representative continuous-flow kinetic traces for huPrP90-231 refolding in varying concentrations of urea at pH 7 (50 mM phosphate buffer)
Figure 3 shows the rate constants corresponding to the two folding phases resolved in continuous-flow experiments plotted (on a semilogarithmic scale) as a function of denaturant concentration, together with the rate constants obtained in our previous stopped-flow measurements 23. Importantly, the rate constants for the slower phase in continuous-flow traces are essentially identical to the rates measured in stopped-flow experiments. This close match provides an internal control for the validity of our kinetic data. The observed rate constants for the fast and slow phases (λ1 and λ2) could be well modeled according to a three state Scheme I:
Figure 3
Figure 3
Urea concentration dependence of rate constants for folding/unfolding of huPrP90-231 at pH 7
where U and N represent the unfolded and native states, respectively, and I represents an on-path folding intermediate. The fit in Figure 3 was obtained by systematic variation of the elementary rate constants (kij) and their dependence on urea concentration (mij) (see eq. 1). The kinetic parameters derived from the best fit of the present data, together with those obtained from previous stopped-flow experiments, are listed in Table 1. Since the fast phase was not directly observed in the stopped-flow experiments, we previously could determine only the preequilibrium constant (KUI) and the corresponding m value (mUI) for the U↔ I transition 23. With a complete set of kinetic data provided by continuous-flow measurements, it is now possible to determine the individual elementary rate constants kUI and kIU, and the corresponding mUI# and mIU# values (Table 1). Importantly, the equilibrium m value, mUI = mUI# + mIU# = 2.1 kJ mol−1M−1, is identical to the mUI parameter obtained previously from our preequilibrium analysis 23, and the free energy associated with the U to I transition, ΔGUI = −RTlnKUI, as calculated from the present data, is in reasonably good agreement with our previous estimate based on stopped-flow measurements alone. Moreover, the global meq and ΔGUN values derived from the kinetic data are very similar to the corresponding parameters obtained from equilibrium experiments, further indicating that the three-state model involving an intermediate ensemble adequately describes the folding of the human prion protein.
Table 1
Table 1
Thermodynamic and kinetic parameters for the folding of huPrP90-231
Folding of the Disease-associated F198S Mutant of huPrP90-231
Based on our recent stopped-flow data, we have concluded that for the majority of PrP variants with mutations linked to familial prion diseases the population of the folding intermediate is much higher as compared to the wild type protein 24. This led us to the working hypothesis that partially structured momomeric intermediates likely play a crucial role in the PrPC→PrPSc conversion. To gain further insight into the effect of pathogenic mutations on prion protein folding pathway, we have extended these studies to continuous-flow measurements. Since these measurements require very large quantities (several hundred milligrams) of highly purified protein, we have focused on one pathogenic variant, F198S, for which the population of the intermediate appears to be especially high 24. This variant, associated with Gerstmann-Straussler-Scheinker disease, was recently shown to undergo a spontaneous conversion to the scrapie-like form in vitro 37.
Similar to the wild type prion protein, the kinetic traces for the refolding of F198S huPrP90-231 could not be approximated as a single exponential, but were well represented by a double exponential function (data not shown for brevity). Furthermore, akin to the wild-type protein, the denaturant-dependence of rate constants for this variant could be quantitatively modeled as a three-state folding process according to Scheme I (Figure 4), with the elementary rate constants, kij, and the mij values listed in Table 1. The ΔGUN and meq values derived from this three-state fit of the kinetic data are in excellent agreement with those estimated from equilibrium measurements (ΔGUN of 21.3 and 21.6 kJ mol−1 and meq of 3.9 kJ and 4.0 kJ mol−1M−1, respectively; see Table 1).
Figure 4
Figure 4
Urea concentration dependence of rate constants for folding/unfolding of the diseases-associated F198S mutant of huPrP90-231 at pH 7
The complete set of rate parameters provided by a combination of continuous-flow and stopped-flow experiments allowed us to calculate the time-dependent evolution of each individual state populated during prion protein folding at different denaturant concentrations. The results of such simulations for the population of the intermediate ensemble for wild-type huPrP90-231 and the F198S variant at 0, 1, 2 and 4 M urea are shown in Figure 5. While the time-course of transient changes in the population of the I state for both proteins is similar, the simulations reveal substantial differences in the population of the intermediate when calculations are extended beyond approximately 10 milliseconds. Since the folding reaction of the prion protein is extremely fast (completed within milliseconds), data calculated for longer times (represented as horizontal lines) provide a reliable measure of the population of the I state under equilibrium conditions. Importantly, at each denaturant concentration, the population of the intermediate species for F198S variant is more than ten-fold higher as compared with the wild-type protein. For the mutant protein, this population under native buffer conditions is about 1 per 250 molecules; it increases further in the presence of the denaturant, reaching the level of 1: 70 and 1:25 molecules in 2 and 4 M urea, respectively. The corresponding values for the wild-type protein are 1:10,000, 1:1100 and 1:300 in the presence of 0, 2 and 4 M urea, respectively. The population of the I state for wild-type huPrP90-231 under native buffer conditions derived from the present data is higher than that of ~1:40,000 previously estimated based on stopped-flow measurements alone 24. The present estimate, based on more complete set of data is more reliable. It should be noted that, in terms of free energy, this discrepancy is relatively small, corresponding to ΔΔGIN of 2.7 kJmol−1.
Figure 5
Figure 5
Time-dependent evolution of the population of the intermediate state, I, during refolding of wild-type huPrP90-231 (left panel) and the F198S variant (right panel) at different urea concentrations in 50 mM phosphate buffer, pH 7
Folding Kinetics of huPrP90-231 at Acidic pH
Our previous stopped flow measurements indicated that the folding intermediate of huPrP90-231 is considerably more stable under mildly acidic conditions (pH 4.8) than at neutral pH 23. However, since in the stopped-flow experiments at low urea concentrations we were able to recover only a small fraction of kinetic amplitudes, calculations based on these measurements could be subject to considerable error. Therefore, we have reexamined the folding of huPrP90-231 at pH 4.8 using the continuous-flow method. As in the case of experiments at neutral pH, the kinetic traces at pH 4.8 were well represented by double exponential functions. Furthermore, the denaturant-dependence of the observed rate constants for the fast and slow phases could be well described according to a three-state folding model, yielding parameters described in the legend to Figure 6. Simulations of experimental data to calculate the population of folding intermediate as a function of time (similar to the one depicted in Figure 5 A for huPrP90-231 folding at pH 7) indicate that, under conditions corresponding to an equilibrium in the absence of any denaturants, the intermediate at pH 4.8 accumulates at the level of approximately 1:300 molecules (as compared to ~1: 10,000 at pH 7.0). The population of the intermediate becomes even higher in the presence of urea, increasing to 1:90 and 1:25 molecules in 2 and 4 M urea, respectively.
Figure 6
Figure 6
Urea concentration dependence of rate constants for folding/unfolding of huPrP90-231 at pH 4.8
A persistent controversy in prion research relates to the normal folding pathway of the prion protein and the nature of direct monomeric precursor that converts to the ligomeric, β-sheet-rich PrPSc state. The formation of amyloid fibrils in a number of other proteins is known to be mediated by monomeric partially folded intermediate states whose population is usually enhanced by disease-related mutations 3840. In the case of the prion protein, however, detection and characterization of putative monomeric intermediates proved to be difficult. In fact, initial studies have concluded that PrP folds by a two-state mechanism without any intermediates, postulating that it is the fully unfolded state that is directly recruited into PrPSc oligomer 22, 41. Only recently has experimental evidence started to emerge indicating the involvement of partially structured monomeric species in prion protein folding and misfolding 23, 24, 4244. A significant part of this evidence comes from kinetic stopped-flow experiments 23, 24. However, detailed interpretation of kinetic data has been hampered by the very fast rate of prion protein folding, with a major part of the reaction occurring within the dead-time of conventional stopped-flow instrumentation. In an effort to overcome this difficulty and other uncertainties in interpretation of stopped-flow data, here we have employed an ultrafast continuous-flow mixing method which allowed us to extend kinetic measurements to early folding events. The present data provides direct and unambiguous evidence for accumulation of partially structured intermediate in early stages of prion protein folding. Formation of this intermediate, at a rate of ~20,000 s−1, is followed by a slower folding step occurring on the millisecond time scale.
The extremely fast rate of early events in prion protein folding is consistent with recent data indicating residual structure in PrP under denaturing conditions; this residual structure might act as a “template” for the native structure, thus accelerating the folding process 44. However, although the present continuous-flow results are fully consistent with - and best described by - a sequential three-state model involving an on-pathway (obligatory) intermediate (Scheme I), one cannot rule out alternative mechanisms involving formation of early nonproductive states (off-pathway intermediates) or mechanisms with parallel pathways. Rigorous discrimination between these alternative models has been possible only in very few cases of model proteins (e.g., bacterial immunity protein Im745 for which there is a tight coupling between the fast and slower folding events, and spectroscopic properties of the native, intermediate and unfolded ensembles are very different (see 31 for further discussion). Unfortunately, these rare conditions are not met for the prion protein.
While the intrinsic limitations of kinetic experiments leave a degree of uncertainty as to whether an early folding intermediate represents a productive and obligatory species in normal folding of the cellular prion protein, the evidence for accumulation of this intermediate has important implication with respect to the mechanism of PrPC conversion into the misfolded PrPSc aggregate. Partially structured folding intermediates are usually characterized by a large exposure of the polypeptide backbone to solvent and relatively high hydrophobicity, enabling intermolecular interactions. Thus, regardless of its specific role in the formation of the unique native structure of PrPC, the partially folded intermediate is a “natural” candidate for a monomeric species that is directly recruited into the aggregated state and, eventually, converts to β-sheet-rich PrPSc structure. The role of this intermediate in the PrPC→PrPSc conversion is further supported by the finding that the intermediate state for PrP variants associated with familial cases of Creutzfeldt-Jakob and Gerstmann-Straussler-Scheinker diseases has increased stability, and is thus more highly populated. This effect, first inferred from our stopped-flow data 24, has now been directly confirmed by a more rigorous approach involving continuous-flow measurements. The present experiments also demonstrate a profound stabilization of the intermediate relative to the native state at mildly acidic pH, correlating nicely with observations that the transition of the recombinant prion protein to β-sheet-rich oligomers 33, 46 and amyloid fibrils (Patel, S., Apetri, A.C., Surewicz, W.K., unpublished data) is strongly promoted under acidic conditions. This is potentially of direct relevance to prion disease pathogenesis, especially in view of previous reports suggesting the involvement of acidic compartments in the PrPC→PrPSc conversion reaction 47.
Acknowledgments
This work was supported by NIH grants NS38604 and NS44158 (to W.K.S.) and GM056250 and CA06927 (to H.R.), and an appropriation from the Commonwealth to the Fox Chase Cancer Center.
Footnotes
Contribution from the Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio 44106 and Basic Science Division, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111
1. Prusiner SB. Science. 1982;216(4542):136–44. [PubMed]
2. Prusiner SB. Proc Natl Acad Sci U S A. 1998;95(23):13363–83. [PubMed]
3. Caughey B. Interactions between prion protein isoforms: the kiss of death? Trends Biochem Sci. 2001;26(4):235–42. [PubMed]
4. Caughey B, Chesebro B. Adv Virus Res. 2001;56:277–311. [PubMed]
5. Collinge J. Annu Rev Neurosci. 2001;24:519–50. [PubMed]
6. Aguzzi A, Polymenidou M. Cell. 2004;116(2):313–27. [PubMed]
7. Weissmann C. Nat Rev Microbiol. 2004;2(11):861–71. [PubMed]
8. Jones EM, Surewicz WK. Cell. 2005;121(1):63–72. [PubMed]
9. Surewicz WK, Jones EM, Apetri AC. Accounts of Chemical Research. 2006 (in press) [PubMed]
10. Castilla J, Saa P, Hetz C, Soto C. Cell. 2005;121(2):195–206. [PubMed]
11. Legname G, Baskakov IV, Nguyen HO, Riesner D, Cohen FE, DeArmond SJ, Prusiner SB. Science. 2004;305(5684):673–6. [PubMed]
12. Tanaka M, Chien P, Naber N, Cooke R, Weissman JS. Nature. 2004;428(6980):323–8. [PubMed]
13. King CY, Diaz-Avalos R. Nature. 2004;428(6980):319–23. [PubMed]
14. Chien P, Weissman JS, DePace AH. Annu Rev Biochem. 2004;73:617–56. [PubMed]
15. Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R, Wuthrich K. Nature. 1996;382(6587):180–2. [PubMed]
16. Zahn R, Liu A, Luhrs T, Riek R, von Schroetter C, Lopez Garcia F, Billeter M, Calzolai L, Wider G, Wuthrich K. Proc Natl Acad Sci U S A. 2000;97(1):145–50. [PubMed]
17. Liu H, Farr-Jones S, Ulyanov NB, Llinas M, Marqusee S, Groth D, Cohen FE, Prusiner SB, James TL. Biochemistry. 1999;38(17):5362–77. [PubMed]
18. Donne DG, Viles JH, Groth D, Mehlhorn I, James TL, Cohen FE, Prusiner SB, Wright PE, Dyson HJ. Proc Natl Acad Sci U S A. 1997;94(25):13452–7. [PubMed]
19. Stahl N, Baldwin MA, Teplow DB, Hood L, Gibson BW, Burlingame AL, Prusiner SB. Biochemistry. 1993;32(8):1991–2002. [PubMed]
20. Caughey BW, Dong A, Bhat KS, Ernst D, Hayes SF, Caughey WS. Biochemistry. 1991;30(31):7672–80. [PubMed]
21. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick RJ, Cohen FE, et al. Proc Natl Acad Sci U S A. 1993;90(23):10962–6. [PubMed]
22. Wildegger G, Liemann S, Glockshuber R. Nat Struct Biol. 1999;6(6):550–3. [PubMed]
23. Apetri AC, Surewicz WK. J Biol Chem. 2002;277(47):44589–92. [PubMed]
24. Apetri AC, Surewicz K, Surewicz WK. J Biol Chem. 2004;279(17):18008–14. [PubMed]
25. Park SH, O’Neil KT, Roder H. Biochemistry. 1997;36(47):14277–83. [PubMed]
26. Ferguson N, Capaldi AP, James R, Kleanthous C, Radford SE. J Mol Biol. 1999;286(5):1597–608. [PubMed]
27. Sanchez IE, Kiefhaber T. J Mol Biol. 2003;325(2):367–76. [PubMed]
28. Oliveberg M. Accounts of Chemical Research. 1998;31:765–772.
29. Krantz BA, Mayne L, Rumbley J, Englander SW, Sosnick TR. J Mol Biol. 2002;324(2):359–71. [PubMed]
30. Shastry MC, Luck SD, Roder H. Biophys J. 1998;74(5):2714–21. [PubMed]
31. Roder H, Maki K, Cheng H. Chem Rev. 2006;106(5):1836–61. [PMC free article] [PubMed]
32. Morillas M, Swietnicki W, Gambetti P, Surewicz WK. J Biol Chem. 1999;274(52):36859–65. [PubMed]
33. Morillas M, Vanik DL, Surewicz WK. Biochemistry. 2001;40(23):6982–7. [PubMed]
34. Zahn R, von Schroetter C, Wuthrich K. FEBS Lett. 1997;417(3):400–4. [PubMed]
35. Khorasanizadeh S, Peters ID, Roder H. Nat Struct Biol. 1996;3(2):193–205. [PubMed]
36. Teilum K, Maki K, Kragelund BB, Poulsen FM, Roder H. Proc Natl Acad Sci U S A. 2002;99(15):9807–12. [PubMed]
37. Vanik DL, Surewicz WK. J Biol Chem. 2002;277(50):49065–70. [PubMed]
38. Kelly JW. Curr Opin Struct Biol. 1998;8(1):101–6. [PubMed]
39. Booth DR, Sunde M, Bellotti V, Robinson CV, Hutchinson WL, Fraser PE, Hawkins PN, Dobson CM, Radford SE, Blake CC, Pepys MB. Nature. 1997;385(6619):787–93. [PubMed]
40. Canet D, Last AM, Tito P, Sunde M, Spencer A, Archer DB, Redfield C, Robinson CV, Dobson CM. Nat Struct Biol. 2002;9(4):308–15. [PubMed]
41. Hosszu LL, Baxter NJ, Jackson GS, Power A, Clarke AR, Waltho JP, Craven CJ, Collinge J. Nat Struct Biol. 1999;6(8):740–3. [PubMed]
42. Nicholson EM, Mo H, Prusiner SB, Cohen FE, Marqusee S. J Mol Biol. 2002;316(3):807–15. [PubMed]
43. Kuwata K, Li H, Yamada H, Legname G, Prusiner SB, Akasaka K, James TL. Biochemistry. 2002;41(41):12277–83. [PubMed]
44. Hosszu LL, Wells MA, Jackson GS, Jones S, Batchelor M, Clarke AR, Craven CJ, Waltho JP, Collinge J. Biochemistry. 2005;44(50):16649–57. [PubMed]
45. Capaldi AP, Shastry MC, Kleanthous C, Roder H, Radford SE. Nat Struct Biol. 2001;8(1):68–72. [PubMed]
46. Swietnicki W, Morillas M, Chen SG, Gambetti P, Surewicz WK. Biochemistry. 2000;39(2):424–31. [PubMed]
47. Caughey B, Raymond GJ, Ernst D, Race RE. J Virol. 1991;65(12):6597–603. [PMC free article] [PubMed]